Korro Bio KRRO
NASDAQ KRRO
$13.06 +0.13 (+1.01%)
As of: Sep 10, 2026 · 3:59 PM EDT

Korro Bio (KRRO) Non-Current Debt (2018 - 2022)

Korro Bio's (KRRO) quarterly Non-Current Debt came in at $4.2 million in Q4 2022, down 70.59% on a YoY basis from $14.2 million in Q4 2021, and down 37.5% quarter-over-quarter from $6.7 million in Q3 2022.

Analysis

Korro Bio (KRRO) Non-Current Debt (2018 - 2022) Analysis & Trends

Korro Bio (KRRO) has reported Non-Current Debt for 5 consecutive years, with $4.2 million the latest figure, recorded in Q4 2022.

  • For the quarter ending Q4 2022, Non-Current Debt fell 70.59% year-over-year to $4.2 million; the trailing twelve-month figure through Dec 2022 stood at $4.2 million (down 70.59% YoY), and the FY2022 full-year result was $4.2 million, down 70.59% from the prior year.
  • Non-Current Debt eased to $4.2 million in Q4 2022 per KRRO's latest filing, from $6.7 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $15.0 million in Q4 2020 and bottomed at $180000.0 in Q4 2019.
  • Historically, Non-Current Debt has averaged $8.9 million across 5 years, with a median of $10.4 million in 2022.
  • The sharpest annual moves came in 2020 and 2022: Non-Current Debt surged 8233.33% in 2020, then tumbled 70.59% in 2022.
  • Over 5 years, Non-Current Debt stood at $349000.0 in 2018, then tumbled by 48.42% to $180000.0 in 2019, then soared by 8233.33% to $15.0 million in 2020, then slipped by 5.55% to $14.2 million in 2021, then plunged by 70.59% to $4.2 million in 2022.
  • According to Business Quant data, Non-Current Debt over the past three periods registered $4.2 million, $6.7 million, and $9.2 million for Q4 2022, Q3 2022, and Q2 2022 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 57.30 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn 26.25 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 1.99 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn -
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn 591.00 Mn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn -
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn 7.29 Bn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn -
10 Korro Bio 231.15 Mn 116.12 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 4.17 Mn
Sep 30, 2022 6.67 Mn
Jun 30, 2022 9.17 Mn
Mar 31, 2022 11.67 Mn
Dec 31, 2021 14.17 Mn
Sep 30, 2021 15.00 Mn
Jun 30, 2021 15.00 Mn
Mar 31, 2021 15.00 Mn
Dec 31, 2020 15.00 Mn
Dec 31, 2019 180,000.00
Sep 30, 2019 222,000.00
Dec 31, 2018 349,000.00